A urine-based approach to NPH differential diagnosis

BioStream is developing a non-invasive platform that combines urine proteomics with AI-supported analysis.

How BioStream Works

Urine collection

A simple urine sample is collected at the clinical point of care.

Proteomic analysis

Laboratory instruments measure a proprietary panel of urine biomarkers.

AI-supported interpretation

Biomarker patterns are analyzed to support a clinician-facing result.

Why Urine?

Simple collection. Deep molecular insight.

Urine enables non-invasive collection at the point of care. BioStream studies proteomic signatures associated with NPH and dementia to support differential diagnosis.

Key Advantages

Non-Invasive Collection

A urine sample can reduce reliance on invasive confirmation procedures such as the spinal tap.

Clinical Workflow

Point-of-care collection is followed by centralized proteomic analysis and a clinician-facing result.

Validation in Progress

An ongoing multi-center study currently includes 100+ hydrocephalus samples and 50 dementia control samples.

As a parent of a CSF shunt and president of the Hydrocephalus Association, I see the need for better monitoring. BioStream’s AI-powered urine test is the solution we’ve been waiting for.

Noa Lubin

President of Hydrocephalus Israel

When I heard about BioStream, I thought—how didn’t I think of this? It solves a daily challenge so simply.

Dr. Ben Guiot

Neurosurgeon